Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it will be
presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and
Investment Forum at the Waldorf Astoria Chicago on May 31, 2019.
Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology
BD&L and Investment Forum is designed to bring together thought leaders
from cancer research institutes, patient advocacy groups, pharma and biotech to
facilitate partnering, funding and investment….
Earlier this month, Genprex’s President and Chief Operating Officer, Julien Pham attended the American Society of Gene & Cell Therapy’s 22ndAnnual Meeting in Washington, D.C., which brings together industry professionals committed to advancing knowledge, awareness and education of gene and cell therapy. This meeting serves as a catalyst to transform medicine by advancing gene and cell therapies to benefit patients and society….
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the services of leading pharmaceutical branding agency, Addison Whitney. Addison Whitney, a Syneos Health company, will draw from its 28-year history to oversee the proprietary and non-proprietary drug naming process for Genprex’s lead drug candidate, currently known as Oncoprex™ immunogene therapy, for non-small cell lung cancer….